Modern therapies improved five-year survival to over 80% in patients diagnosed with eosinophilic heart disease.
Eosinophilic heart disease is a rare, potentially fatal condition requiring high clinical suspicion, multimodal imaging, and endomyocardial biopsy for diagnosis, with treatment tailored to the underlying etiology.
Abstract: Eosinophilic heart disease (EHD) is an inflammatory cardiac disorder characterized by the infiltration and subsequent heart tissue damage mediated by eosinophils. The clinical manifestations of EHD vary widely, ranging from asymptomatic to severe, life-threatening conditions. Diagnosis relies on a multimodal approach, incorporating clinical presentations, laboratory findings (e.g. hypereosinophilia), and advanced imaging studies such as cardiac magnetic resonance imaging (MRI) and echocardiography. However, the gold standard for definitive diagnosis remains endomyocardial biopsy, which demonstrates eosinophilic infiltration and associated myocardial injury. Currently, there is no established consensus on specific therapeutic protocols for EHD. Management primarily targets the underlying etiology and mitigates eosinophil-induced cardiac damage. Prognosis is highly variable and largely dependent on the causative pathology, with outcomes spanning from rapidly progressive and fatal courses to indolent, chronic disease progression. Given the heterogeneity in clinical presentation and treatment responses, there is an urgent need for evidence-based clinical guidelines to standardize the management of EHD. Keywords: eosinophilic heart disease, hypereosinophilia, clinical presentation, endomyocardial biopsy, prognosis
Dong et al. (2026) conducted a review in Patients with eosinophilic heart disease characterized by eosinophilic infiltration causing myocardial injury. Modern therapies improved five-year survival to over 80% in patients diagnosed with eosinophilic heart disease.